Sestrin2 mitigates obesity-associated HFpEF via adaptive IRE1α-XBP1 signaling and redox regulation.
It is demonstrated that Sestrin2 has cardioprotective effects on obesity-associated HFpEF and is associated with the activation of adaptive IRE1α-XBP1 signaling involving Sigmar1, together with improved metabolic and redox homeostasis.